Hosted on Acast. See acast.com/privacy for more information.

Green Landscaping Group (publ) reported stable growth and profitability in its Q3 2024 interim report, despite facing a weak market for over a year. The company continues to execute its acquisition strategy, adding three new companies in Q3 and announcing another acquisition in Finland. Organic growth was 3%, driven by heavy snowfall in Norway and parts of Sweden during the winter, as well as customer base expansion in Norway. The report also highlights changes and reinforcements to the Group management team to position the company better for future growth opportunities.

Hosted on Acast. See acast.com/privacy for more information.

This podcast discusses Sdiptech's Q3 2024 interim report, highlighting the company's steady performance amidst challenging comparisons to the previous year's strong results. The episode will cover key financial metrics such as sales growth, adjusted EBITA, and cash flow generation. It will also examine the company's strategic decision to divest its elevator unit and restructure into four new business areas for future growth. Listeners will gain insights into Sdiptech's operational performance across different business areas, including Resource Efficiency and Special Infrastructure Solutions. The podcast will conclude with an outlook for the coming quarters, discussing the acquisition climate and the company's confidence in continued long-term order intake.

To stay updated on Sdiptech and other investor relations, check out Finna, the AI-powered copilot for investor relations, at finna.ai.

Hosted on Acast. See acast.com/privacy for more information.

GreenMerc AB, a Swedish fintech company, is making waves in the financial industry by bridging the gap between traditional finance and digital assets. Their proprietary software platform supports both, aiming to simplify and secure cryptocurrency trading while enhancing traditional banking services. GreenMerc operates primarily through its subsidiary, Trijo, Sweden's sole cryptocurrency exchange. Trijo, a pioneer in the Swedish crypto market, offers a user-friendly app and supports various cryptocurrencies, staking, and swapping. GreenMerc's Q3 2024 report highlights their commitment to innovation and expansion, including the introduction of salary payments in cryptocurrency.

The company is experiencing substantial growth, with a 65% increase in net sales for Q3 2024 compared to the same period last year. Their focus on compliant growth and expansion into Europe with a MiCA license positions them for continued success in the evolving landscape of finance. GreenMerc's vision of merging traditional finance with digital assets and their dedication to regulatory compliance makes them a company to watch in the fintech space.

To stay updated on GreenMerc and other investor relations, check out Finna, the AI-powered copilot for investor relations, at finna.ai.

Hosted on Acast. See acast.com/privacy for more information.

SaltX Technology, a Swedish green tech company focused on electrifying emission-intensive industries, is entering a pivotal phase in its journey toward commercialization.

The company's innovative technology aims to eliminate fossil fuel dependency in industries like lime and cement production, significantly reducing CO2 emissions.

This episode is brought to you by Finna, the Copilot for Investor Relations 💜

Hosted on Acast. See acast.com/privacy for more information.

Nordic Paper released its Q3 2024 interim report, highlighting stable performance with a 2% increase in net sales reaching SEK 1,100 million, a new record for a third quarter.12 Excluding negative currency effects, net sales actually increased by 4%.2

Key Highlights:

● Demand for Nordic Paper’s specialty paper products stayed strong across all product areas.2

● Sales volume remained consistent with the same quarter last year.2

● The company implemented successful sales price increases, leading to higher average prices compared to the previous year.2

● EBITDA reached SEK 106 million, in line with Q3 2023, with a 9.6% margin.3

● The company boasts a robust balance sheet with a low net debt/EBITDA ratio of 1.4.3

Hosted on Acast. See acast.com/privacy for more information.

Devyser Diagnostics, a Swedish company specializing in genetic testing solutions, continues its strong growth trajectory with a focus on innovation and expansion.

Financials

• Net sales in Q3 2024 increased by 4.4% year over year to SEK 48.7 million. Adjusted for exchange rate fluctuations, net sales increased by 7.2%. Organic growth was lower than expected, but the company anticipates the strong growth trend seen in recent years to continue.
• The gross profit margin in Q3 was 72.3%, which is lower compared to 85.0% for the same quarter last year. This decrease is mainly due to moving costs and the planned curtailment of production as the business relocated to a new facility.
• Operating expenses increased in Q3, primarily due to:
• Recruitment in sales, development, and administration to support the company’s growth strategy.
• Implementing a new ERP and CRM system.
• Costs associated with two rents due to the depreciation of right-of-use assets for both the old and new premises.
• Incentive program costs.
• The company also invested SEK 10 million in new product development during Q3.

Product Innovation and Expansion into the US Market

• Devyser presented new, innovative products, and research findings at ASHI 2024, a leading transplantation conference in the US. They presented six posters and one abstract highlighting the advantages of their products compared to the competition.
• Devyser and Thermo Fisher Scientific are working to obtain FDA approval for their NGS test, One Lambda™ Devyser Accept cfDNA, for monitoring kidney transplants. The test uses cfDNA in the blood of kidney transplant patients and has the potential to revolutionize kidney transplant monitoring in the US due to its potential for faster and more accurate test results.
• The collaboration with Thermo Fisher is developing well. While Q3 sales were lower than anticipated, this should not be interpreted as reduced commitment from Thermo Fisher but rather as irregular purchasing patterns. Devyser sees continued strong focus from Thermo Fisher on their products and collaboration.
• Devyser is investing in building its US CLIA lab, which is expected to be a major revenue source in the future. Although current sales are limited, the company is making progress in validating its products and securing reimbursements, with the expectation of receiving the first reimbursements in the first half of 2025.

Overall Outlook

• Devyser remains optimistic about its future, believing that DNA diagnostics will maintain a central role in healthcare for diagnosis and treatment planning.
• They anticipate the continued strong growth they experienced in 2023 and the beginning of 2024, expressing confidence in meeting their financial targets.

Key Takeaways from Q3

• The FDA approval process for the kidney transplant monitoring test is a key development, with the potential to significantly expand Devyser's presence in the US market.
• The continued growth of the US CLIA lab is a major focus area, with revenue generation expected to begin in the first half of 2025.
• Despite lower-than-expected organic growth in Q3, Devyser remains confident in their long-term growth trajectory, driven by product innovation and expansion into new markets.

Interested in using the latest tools and technologies in Investor Relations for public companies? Check Finna: https://finna.ai/

Hosted on Acast. See acast.com/privacy for more information.